While the impact on participants' bottom lines remains to be seen, some lab company leaders said they expect to see other payors explore similar plans.
The firm's clinical service revenues were up also 51 percent, and it also announced it has signed a contract with insurer Humana.
The companies were involved in a dispute over NeoGenomics' handling of Health Discovery technology it licensed in 2012 to develop cancer tests.
Test volumes, revenues per test and costs per test improved during the quarter, company executives said.
The 360Dx Index was up 12 percent last month as shares of Accelerate Diagnostics, Veracyte, and Exact Sciences each improved more than 40 percent month over month.
Veracyte was the only company in the 360Dx Index whose stock price rose last month while NantHealth, NeoGenomics, and Accelerate Diagnostics saw sharp declines.
Qiagen will provide IUO tests for NeoGenomics to verify, set up, and run in clinical trials and in anticipation of regulatory approval.
NeoGenomics estimates that the more than 2,000 community oncologists represent a $2.5 billion testing opportunity. Its CEO called the segment a "strategic priority."
Just five of the 28 firms in the 360Dx Index saw their share prices rise last month. Veracyte led the gainers, while Accelerate Dx had the sharpest decline.